Observations
Circulating ghrelin concentrations are reduced in healthy offspring of Type 2 diabetic subjects, and are increased in women independent of a family history of Type 2 diabetes
To the Editor: Ghrelin is a new 28 amino acid acylated peptide hormone [1] identified as the endogenous ligand for the growth hormone secretagogue receptor. In both animals and humans ghrelin stimulates food intake [1, 2] and is reversibly influenced by energy status, decreased in obesity [3] and increased in food deprived conditions [4] . These findings, together with potential effects on glucose homeostasis, makes ghrelin a potentially important player in the pathophysiology of Type 2 diabetes.
Healthy offspring of Type 2 diabetic patients have often been considered a model of studying the early metabolic aberrations in the development of Type 2 diabetes. We sought to determine the involvement of ghrelin in the possible development of Type 2 diabetes by comparing fasting circulating concentrations of ghrelin in 23 healthy but insulin resistant first degree relatives of Type 2 diabetic patients, and 16 healthy control subjects matched by age, sex, and BMI. All gave written consent to participate and the study was approved by the local ethics committee of the county of Aarhus and conducted in accordance with the guidelines proposed in the Declaration of Helsinki.
All subjects were examined by measuring anthropometric variables, body-composition, fasting samples of plasma ghrelin, and an OGTT (75 g). On a subsequent day, a 150 min hyperinsulinaemic (0.6 mU·kg -1 ·min -1 ) euglycaemic clamp was carried out to assess insulin-stimulated glucose uptake (M-value).
Plasma samples were collected in tubes with aprotinin/ EDTA solution in an ice bath and frozen immediately and kept at -80°C. Total plasma ghrelin was measured with a radioimmunoassay as described previously [5] . Plasma glucose was measured immediately after sampling (Beckman Instruments, Palo Alto, Calif., USA). Serum insulin was determined by ELISA, and body composition was evaluated by dual energy X-ray absorptiometry.
Data are given as means±SD or geometric mean and range, as appropriate. Student's two-tailed t test for unpaired data was used for comparison of data between groups. Correlations were examined using Pearson's correlation analysis. Furthermore, data were analysed by using multivariate linear regression analysis with ghrelin as the dependent variable. Due to the graphical impression of a curvilinear relation between insulin and ghrelin, an exponential model was applied. All statistical analyses were done by using SPSS for Windows version 10.0 (SPSS, Chicago), and a p value of less than 0.05 was considered statistically significant.
The offspring group was insulin-resistant compared to the control group (M-value; 4.52±1.87 vs. .05), were higher in the offspring group. Men and women were comparable with respect to age, BMI, and insulinaemia, but, as expected, women were characterized by an increased body fat content.fmol/ml, p=0.012] (Fig. 1A) . In both groups plasma ghrelin concentrations were higher in females compared to males [offspring: 165.0 (94.9-237.0) vs 117.2 (55.9-187.9) fmol/ml, p<0.05 and controls: 220.8 (168.0-287.7) vs 158.6 (97.0-228.4) fmol/ml, p<0.05].
In multivariate linear regression analysis in a model including family history of Type 2 diabetes (yes/no), sex (male/ female), BMI, and fasting serum insulin (the natural logarithm to insulin), only family history of Type 2 diabetes, sex, and insulinaemia significantly determined the concentration of plasma ghrelin (r 2 =0.52, p<0.001, backwards analysis). Other measures of insulinaemia employed in the model, e.g. mean and integrated insulin during the OGTT, and early insulin secretory response (0-30 min) of the OGTT, did not alter determinants of plasma ghrelin. Analogously, other estimates of body weight (total body weight, lean body mass, body fat, and body fat %) did not influence plasma ghrelin.
By using the final model, we have produced estimated values of plasma ghrelin by serum insulin, in the groups: offspring men, offspring women, and control men, and control women, respectively. This is graphically displayed in (Fig. 1B) .
Our study shows that fasting circulating concentrations of ghrelin are reduced in first degree relatives of Type 2 diabetic patients. We found plasma ghrelin to be significantly determined by circulating insulin concentrations. Another novel observation is a sex-dependent difference in ghrelin concentrations, i.e. women showing higher concentrations of circulating ghrelin although women had a higher body fat content, which has been associated with suppressed ghrelin concentrations [3, 6] . One could speculate that sex hormones influence ghrelin secretion or elimination, possibly through a growth hormone feedback mechanism.
In previous reports ghrelin has been found to be decreased in obese subjects, and in lean healthy Pima Indians-two phenotypes also at high risk of developing Type 2 diabetes [3] . Recent reports have indicated that ghrelin is differentially expressed in Type 2 diabetes dependent on body composition [6] . In obese Type 2 diabetic subjects ghrelin was found to be decreased whereas it was found to be increased in utmost lean (BMI<18.5) Type 2 diabetic patients [6] . This could suggest that neither Type 2 diabetes nor insulin resistance per se have an independent role in determining ghrelin concentrations. However, lean and obese Type 2 diabetes subjects are known to differ with respect to the metabolic components of the disease. Consequently, the increased concentration of ghrelin in lean Type 2 diabetic subjects [6] , could be due to the markedly low body mass and the presumably lower insulin secretion in this subgroup of Type 2 diabetic patients. These circumstances probably mask the true relevance of ghrelin in Type 2 diabetes and the metabolic syndrome.
The causality between increased concentrations of insulin and reduced concentrations of ghrelin cannot be determined by this study. We speculate whether the reduced concentrations of ghrelin in offspring of Type 2 diabetic subjects are a consequence of increased insulin concentrations. In support of this, a reciprocal relation between insulin and ghrelin was documented experimentally in healthy subjects [7] . Another study did not find this relation [8] , but this possibly reflects that a sustained increase in insulinaemia is required to influence ghrelin concentrations.
In summary, this study shows that circulating ghrelin is reduced in a group of healthy subjects at high risk of developing Type 2 diabetes. We found that the compensatory hyperinsulinaemia due to insulin resistance was associated with significantly reduced ghrelin concentrations, thereby suggesting new mechanisms of ghrelin regulation. Moreover, this study shows that women have higher values of ghrelin. Fig. 1 . A Box-and-whisker plot: median, lower and upper quartiles (box), and 5th and 95th percentiles (whiskers), and outliers, comparing fasting plasma ghrelin (mean±SEM) in healthy first degree relatives of Type 2 diabetic patients (n=23) (open box), and a control group (n=16) (hatched box) matched by age, sex and BMI. p <0.01 (Students t test) . B Estimated values of plasma ghrelin by serum-insulin in offspring men, offspring women, control men and control women, respectively, using the final model estimated by multiple regression analysis: plasma ghrelin =627*e (-0.251*group) *e (-0.351*sex) *serum-insulin -0.306
An E23K single nucleotide polymorphism in the islet ATP-sensitive potassium channel gene (Kir6.2) contributes as much to the risk of Type II diabetes in Caucasians as the PPARγ Pro12Ala variant
To the Editor: The search for the Type II (non-insulin-dependent) diabetes mellitus gene(s) has proven to be a challenge. It is still not known whether common or rare variants are involved and if these susceptibility loci will have a single allele altering risk or if combinations of these variants will affect risk. For example, the PPARγ Pro12Ala variant has consistently been shown to be associated with risk of Type II diabetes [1, 2] . We believe that the Kir6.2 E23K SNP should also be considered as a Type II diabetes risk altering polymorphism. Kir6.2 (KCNJII gene on 11p15.1) is a subunit of the inwardly rectifying ATP sensitive K+ channel, which is involved in the regulation of insulin secretion in pancreatic beta cells [3] . We have reported an association between the Kir 6.2 E23K homozygous genotype (KK) and Type II diabetes in a case-control meta-analysis [4] . Most recently, electrophysiological studies in which human isoforms of Kir6.2 in COS-1 cells were used, showed a dose-dependent reduction in ATP sensitivity of the Kir6.2 E23K variant [5] . Hence, we decided to re-evaluate the common E23K polymorphism by genotyping an additional population (Ashkenazi Jewish) and including the United Kingdom Prospective Diabetes Study (UKPDS) data [6] . We assessed the relative risk associated with the (K) allele and the homozygous E23K (KK) status.
In the original study, we analysed 521 Type II diabetic patients and 367 control subjects, where the E23K variant was more frequent in the patients than in the control subjects (0.19 vs 0.11, p=0.0016; corrected p<0.01). All subjects in our study gave their informed consent. In the Ashkenazi sample, the frequency of the KK genotype in the Type II diabetic patients (0.15) compared with the control subjects (0.10) tended in the same direction but was not significant (p=0.097). However, Fig. 1 . A Estimated allele relative risk (95% CI) for Kir 6.2 E23K in six combined Caucasian studies. The circle for each study indicates the average relative risk observed for the "K" allele. The line represents range of the 95% CI around the estimated risk. The dashed line represents the 95% CI for the current combined data. B Estimated genotypic relative risk
